[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dry-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dry-syndrome":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100590709","early-phase-1-early-clinical-study-of-utaa91-injection-for-the-treatment-of-relapsedrefractory-autoimmune-diseases-100590709",false,"NCT06970951","Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed\u002FRefractory Autoimmune Diseases","A Single-Arm, Open-Label, Single-Center Investigator-Initiated Early-Stage Clinical Study for Relapsed\u002FRefractory (R\u002FR) Autoimmune Diseases","Inclusion Criteria\n\n1. Age ≥ 18 years (including the cut - off value), with no restrictions on gender.\n2. Expected survival time ≥ 3 months.\n3. Subjects with relapsed\u002Frefractory autoimmune diseases who have failed standard treatment or lack effective treatment options, including but not limited to rheumatoid arthritis, systemic sclerosis, systemic lupus erythematosus, idiopathic inflammatory myopathies, Sjögren's syndrome, connective tissue disease - related interstitial lung disease, immune thrombocytopenia, primary biliary cholangitis, etc.\n4. Liver and kidney functions and cardiopulmonary functions meet the requirements.\n5. No severe mental disorders.\n6. Able to understand this trial and have signed the informed consent form.\n\nExclusion Criteria\n\n1. Malignant tumors other than relapsed\u002Frefractory autoimmune diseases (R\u002FR AID) within 5 years before screening.\n2. Subjects with positive virus and\u002For syphilis tests.\n3. Presence of severe heart disease or unstable systemic diseases.\n\n5\\. Presence of active or uncontrollable infections requiring systemic treatment.\n\n6\\. Pregnant or breastfeeding women, as well as female subjects who plan to become pregnant within 2 years after cell infusion or male subjects whose partners plan to become pregnant within 2 years after their cell infusion.\n\n7\\. Subjects who have received CAR - T therapy or other gene - modified cell therapies before screening.","ALL","18 Years",{"count":19,"type":20},15,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study. The primary objective is to evaluate the safety of UTAA91 injection in treating subjects with relapsed\u002Frefractory autoimmune inflammatory diseases (AID).",[26,27,28,29,30],"Systemic Lupus Erythematosus","Rheumatoid Arthritis","Dry Syndrome","Idiopathic Inflammatory Myopathies","Systemic Sclerosis","NOT_YET_RECRUITING","2025-05-06",{"date":34,"type":35},"2025-05-14","ACTUAL",{"date":37,"type":20},"2025-05-18",{"date":39,"type":20},"2027-04-30",{"name":41,"class":42},"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":43},"100568368","ultrasonic-comparison-of-salivary-glands-in-autoimmune-diseases-cougar-100568368","NCT06680310","Ultrasonic COmparison of Salivary Glands in Autoimmune Diseases (COUGAR)","Prospective Multicenter Study of Ultrasound Evaluation of Salivary Glands in Patients with Sjögren's Disease Compared with Patients with Connective Tissue Diseases (lupus, Scleroderma, Rheumatoid Arthritis) and Healthy Subjects with Dry Syndromes","COUGAR","Inclusion Criteria:\n\n* Major patients\n* Patients fulfilling Sjogren criteria (2012 and 2016 American-European criteria) or Lupus according to ACR 2019 criteria or RA according to ACR\u002FEULAR 2010 criteria or scleroderma according to ACR-EULAR 2013 classification criteria or control patient (patient with dry syndrome felt without pre-cited autoimmune disease).\n\nExclusion Criteria:\n\n* Uncooperative patient who has refused to participate in the study.\n* Patients unable to understand the protocol, under guardianship or curatorship.\n* Patients not affiliated to the French Social Security system.",{"count":53,"type":20},501,"OBSERVATIONAL","Prospective multicenter cross-sectional study evaluating ultrasound of the main salivary glands (2 parotid and 2 submandibular) in patients with Sjögren's disease compared with patients with other connective diseases (rheumatoid arthritis (RA), lupus, scleroderma) and control patients (patient with dry syndrome without the above-mentioned autoimmune disease).",[57,28,58,59,27],"Sjogren Syndrome","Lupus","Scleroderma","2024-11-07",{"date":62,"type":35},"2024-11-08",{"date":64,"type":20},"2024-12-01",{"date":66,"type":20},"2025-12-01",{"name":68,"class":69},"University Hospital, Brest","OTHER"]